| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1572-0241.2007.01466.X |
| P698 | PubMed publication ID | 17850410 |
| P2093 | author name string | Robert P Myers | |
| Abdel Aziz M Shaheen | |||
| Alex F Wan | |||
| P2860 | cites work | Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C | Q24563264 |
| Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study | Q24680285 | ||
| Conducting systematic reviews of diagnostic studies: didactic guidelines | Q24797459 | ||
| The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews | Q24801517 | ||
| Meta-analysis in clinical trials | Q27860779 | ||
| Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews | Q29619492 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| Diagnosis, management, and treatment of hepatitis C | Q29620656 | ||
| Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data | Q30703091 | ||
| Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. | Q33235606 | ||
| Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests | Q33806407 | ||
| Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy | Q33866383 | ||
| The diagnostic odds ratio: a single indicator of test performance | Q34276416 | ||
| Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. | Q34326379 | ||
| Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations | Q34342972 | ||
| Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. | Q34390093 | ||
| Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection | Q34438649 | ||
| Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease? | Q34537738 | ||
| Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. | Q34544284 | ||
| A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. | Q34560349 | ||
| Role of liver biopsy in management of chronic hepatitis C: a systematic review | Q34984098 | ||
| Controversies in liver biopsy: who, where, when, how, why? | Q35628105 | ||
| Development and validation of methods for assessing the quality of diagnostic accuracy studies | Q35802603 | ||
| A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure | Q35914841 | ||
| Current and future concepts in hepatitis C therapy | Q36054696 | ||
| Challenges in systematic reviews of diagnostic technologies | Q36169156 | ||
| Performance of serum marker panels for liver fibrosis in chronic hepatitis C. | Q36373907 | ||
| Reversal of hepatic fibrosis -- fact or fantasy? | Q36382260 | ||
| Noninvasive measures of liver fibrosis | Q36382285 | ||
| Identifying relevant studies for systematic reviews | Q36888457 | ||
| Progression of liver fibrosis among injection drug users with chronic hepatitis C. | Q40339820 | ||
| Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C virus (HCV) infection: assessment using transient elastometry and the role of HCV genotype 3. | Q42998761 | ||
| Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies | Q43875837 | ||
| Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model | Q44151781 | ||
| Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C. | Q44162463 | ||
| Meta-analysis of diagnostic test accuracy assessment studies with varying number of thresholds | Q44767951 | ||
| The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C. | Q44785887 | ||
| Usefulness of elastometry in evaluating the extents of liver fibrosis in hemophiliacs coinfected with hepatitis C virus and human immunodeficiency virus | Q45416498 | ||
| Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients | Q45421063 | ||
| Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus | Q45421359 | ||
| Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients | Q45728692 | ||
| Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial | Q45733502 | ||
| Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study | Q45737816 | ||
| Non-invasive biomarkers of liver fibrosis in haemophilia patients with hepatitis C: can you avoid liver biopsy? | Q45859625 | ||
| Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. | Q46668333 | ||
| Noninvasive markers of fibrosis for longitudinal assessment of fibrosis in chronic liver disease: are they ready for prime time? | Q46675147 | ||
| A novel panel of blood markers to assess the degree of liver fibrosis | Q46827711 | ||
| A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers | Q46942363 | ||
| Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. | Q46953851 | ||
| The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. | Q47372679 | ||
| Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics | Q47580647 | ||
| Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin | Q47732710 | ||
| Sampling variability of liver fibrosis in chronic hepatitis C. | Q48583601 | ||
| Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. | Q51545030 | ||
| Efficacy of non-invasive elastometry on staging of hepatic fibrosis | Q51670885 | ||
| Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. | Q51927013 | ||
| Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. | Q51945661 | ||
| Nonparametric estimation of ROC curves in the absence of a gold standard | Q51969479 | ||
| Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients | Q51982985 | ||
| Serum markers detect the presence of liver fibrosis: a cohort study | Q51983072 | ||
| Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors | Q51990048 | ||
| Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index | Q58622790 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systematic review | Q1504425 |
| diagnosis | Q16644043 | ||
| P304 | page(s) | 2589-2600 | |
| P577 | publication date | 2007-09-10 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | The American Journal of Gastroenterology | Q7713501 |
| P1476 | title | FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy | |
| P478 | volume | 102 |
| Q30442208 | A Health Technology Assessment of Transient Elastography in Adult Liver Disease |
| Q30476922 | A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation |
| Q41972577 | A new index for non-invasive assessment of liver fibrosis |
| Q30472903 | A new scoring system for prediction of fibrosis in chronic hepatitis C. |
| Q28070268 | ARFI: from basic principles to clinical applications in diffuse chronic disease-a review. |
| Q57818202 | Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: A pilot study |
| Q34018236 | Accuracy of ultrasound to identify chronic liver disease. |
| Q86381962 | Acoustic radiation force impulse imaging for non‐invasive assessment of liver fibrosis in chronic hepatitis B |
| Q34792158 | Angiopoietin-2 Serum Levels Improve Noninvasive Fibrosis Staging in Chronic Hepatitis C: A Fibrogenic-Angiogenic Link |
| Q40428093 | Angiopoietin-2/angiopoietin-1 as non-invasive biomarker of cirrhosis in chronic hepatitis C. |
| Q52985570 | Assessment of fibrotic tissue and microvascular architecture by in-line phase-contrast imaging in a mouse model of liver fibrosis |
| Q34209648 | Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers |
| Q37536973 | Assessment of liver fibrosis: noninvasive means |
| Q39278672 | Assessment of transient elastography in Japanese patients with non-alcoholic fatty liver disease |
| Q51102598 | Baseline and serial liver stiffness measurement in prediction of portal hypertension progression for patients with compensated cirrhosis |
| Q30426512 | Biomarkers of disease differentiation: HCV recurrence versus acute cellular rejection |
| Q37323789 | Biomarkers of liver fibrosis |
| Q37825547 | Biomarkers of liver fibrosis |
| Q37897194 | Biomarkers of liver fibrosis: what lies beneath the receiver operating characteristic curve? |
| Q35904838 | Burden of Liver Disease among Community-Based People Who Inject Drugs (PWID) in Chennai, India |
| Q35180503 | Change in fibrosis score as a predictor of mortality among HIV-infected patients with viral hepatitis |
| Q58622691 | Chapter 4 Biomarkers Of Liver Fibrosis |
| Q41678369 | Checkmate to liver biopsy in chronic hepatitis C? |
| Q26825671 | Chronic hepatitis C and liver fibrosis. |
| Q28660820 | Cirrhosis and other liver disease in cystic fibrosis |
| Q26852557 | Clinical Application of Transient Elastography in the Diagnosis of Liver Fibrosis: an Expert Panel Review and Opinion |
| Q26828052 | Clinical applications of transient elastography |
| Q83721888 | Clinical feasibility of liver elastography by acoustic radiation force impulse imaging (ARFI) |
| Q21261905 | Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis |
| Q51701375 | Comparison of surrogate serum markers and transient elastography (Fibroscan) for assessing cirrhosis in patients with chronic viral hepatitis |
| Q51509141 | Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C. |
| Q33718346 | Controlled attenuation parameter for evaluating liver steatosis in chronic viral hepatitis. |
| Q34098870 | Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients |
| Q38858344 | Critical comparison of elastography methods to assess chronic liver disease |
| Q54234625 | Diagnosis and staging of fibrosis in patients with chronic hepatitis C: comparison and critical overview of current strategies |
| Q64065840 | Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis |
| Q38996426 | Diagnostic accuracy of transient elastography (FibroScan) in detection of esophageal varices in patients with cirrhosis: A meta-analysis |
| Q43582427 | Diagnostic value of fibronectin discriminant score for predicting liver fibrosis stages in chronic hepatitis C virus patients |
| Q35915477 | Direct and Indirect Serum Markers of Liver Fibrosis Compared with Transient Elastography among Women in the Women's Interagency HIV Study |
| Q30458298 | Discordance between Liver Biopsy and FibroTest in Assessing Liver Fibrosis in Chronic Hepatitis B |
| Q37214588 | Effective use of FibroTest to generate decision trees in hepatitis C. |
| Q44297171 | Effectiveness of direct-acting antiviral therapy for hepatitis C in difficult-to-treat patients in a safety-net health system: a retrospective cohort study |
| Q48646156 | Efficacy of transient elastography in screening for large esophageal varices in patients with suspicious or proven liver cirrhosis |
| Q43185946 | Exceeding the limits of liver histology markers |
| Q57735452 | Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients |
| Q45352070 | Feasibility and reliability of the FibroScan S2 (pediatric) probe compared with the M probe for liver stiffness measurement in small adults with chronic liver disease |
| Q83522860 | FibroScan and ultrasonography in the prediction of hepatic fibrosis in patients with chronic viral hepatitis |
| Q42535299 | FibroScan® access in Canada: Time for reform, a call for universal access |
| Q57389448 | FibroTest, transient elastography method, and combined FibroTest and transient elastography method for diagnosis of severe hepatic fibrosis and cirrhosis in adults with chronic hepatitis C |
| Q38188809 | FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis. |
| Q40462698 | Genomics and proteomics in liver fibrosis and cirrhosis. |
| Q47142488 | Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update). |
| Q37368417 | HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir. |
| Q37886275 | HCV-related liver cancer in people with haemophilia. |
| Q37391122 | HIV-related liver disease: ARV drugs, coinfection, and other risk factors |
| Q52977976 | Hepatic Vein Arrival Time for Diagnosis of Liver Cirrhosis: A 10-Year Single-Center Experience With Contrast-Enhanced Sonography |
| Q34966853 | Hepatitis C and kidney disease: An overview and approach to management |
| Q38552198 | Hepatitis C infection and chronic renal diseases |
| Q40989823 | Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs. |
| Q37777154 | Hepatitis C virus recurrence after liver transplantation: biomarkers of disease and fibrosis progression. |
| Q36997093 | Highlights of the Fourth Canadian Symposium on Hepatitis C: Moving towards a National Action Plan |
| Q43046834 | How far is noninvasive assessment of liver fibrosis from replacing liver biopsy in hepatitis C? |
| Q37009627 | Impact of antibody to hepatitis B core antigen on the clinical course of hepatitis C virus carriers in a hyperendemic area in Japan: A community-based cohort study. |
| Q39210299 | Invasive and non-invasive assessment of portal hypertension. |
| Q30473767 | Is it better to use two elastographic methods for liver fibrosis assessment? |
| Q34757469 | Is spleen circulation impaired in systemic sclerosis and what is the role of liver fibrosis? |
| Q92669625 | Is there still a role for liver biopsy in managing hepatitis C virus infections? |
| Q38859235 | JSUM ultrasound elastography practice guidelines: liver |
| Q36032750 | Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study |
| Q40685164 | Liver Fibrosis Evaluation Using Real-time Shear Wave Elastography in Hepatitis C-Monoinfected and Human Immunodeficiency Virus/Hepatitis C-Coinfected Patients. |
| Q37014193 | Liver Fibrosis Linked to Cognitive Performance in HIV and Hepatitis C |
| Q34469006 | Liver biopsy for histological assessment: The case against |
| Q34469014 | Liver biopsy for histological assessment: The case in favor |
| Q37577564 | Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). |
| Q85631958 | Liver stiffness measurement in cirrhotic patient — Implications of disease activity and treatment efficacy |
| Q30403258 | MR Elastography of Liver Disease: State of the Art. |
| Q53222636 | Molecular imaging of hepatic stellate cell activity by visualization of hepatic integrin αvβ3 expression with SPECT in rat. |
| Q38116627 | New Technologies in Clinical Ultrasound |
| Q36652084 | New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis |
| Q42160967 | Non-biopsy methods to determine hepatic fibrosis. |
| Q33421239 | Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy |
| Q37613375 | Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease |
| Q26744631 | Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy? |
| Q42406716 | Non-invasive assessment of liver fibrosis |
| Q98165162 | Non-invasive assessment of liver fibrosis in alcoholic liver disease |
| Q30474738 | Non-invasive assessment of liver fibrosis in chronic hepatitis C |
| Q41278105 | Non-invasive assessment of liver fibrosis in chronic viral hepatitis. |
| Q40707349 | Non-invasive assessment of liver fibrosis in patients with chronic hepatitis B. |
| Q37801658 | Non-invasive assessment of liver fibrosis: it is time for laboratory medicine |
| Q30442641 | Non-invasive diagnosis of hepatitis B virus-related cirrhosis |
| Q34892910 | Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B. |
| Q30381236 | Noninvasive Measures of Liver Fibrosis and Severity of Liver Disease. |
| Q64101542 | Noninvasive Tests to Monitor Methotrexate-Induced Liver Injury |
| Q30436164 | Noninvasive diagnosis of cirrhosis: a review of different imaging modalities |
| Q30401743 | Noninvasive methods, including transient elastography, for the detection of liver disease in adults with cystic fibrosis |
| Q27488886 | Novel Serum Markers of Fibrosis Progression for the Follow-Up of Hepatitis C Virus-Infected Patients |
| Q36310780 | Panel of three novel serum markers predicts liver stiffness and fibrosis stages in patients with chronic liver disease |
| Q35216606 | Patient preference and willingness to pay for transient elastography versus liver biopsy: A perspective from British Columbia |
| Q37278359 | Percutaneous liver biopsy practice patterns among Canadian hepatologists |
| Q37975255 | Performance of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis: a pooled meta-analysis. |
| Q30459104 | Performance of liver stiffness measurements by transient elastography in chronic hepatitis. |
| Q37841383 | Performance of the Aspartate Aminotransferase-to-Platelet Ratio Index for the Staging of Hepatitis C-Related Fibrosis: An Updated Meta-Analysis §Δ |
| Q26777483 | Personalized management of cirrhosis by non-invasive tests of liver fibrosis |
| Q26823671 | Prediction of fibrosis progression in chronic viral hepatitis |
| Q38434496 | Prognostic value of the combined use of transient elastography and fibrotest in patients with chronic hepatitis B. |
| Q35908687 | Prospective Validation of FibroTest in Comparison with Liver Stiffness for Predicting Liver Fibrosis in Asian Subjects with Chronic Hepatitis B |
| Q34359330 | Prospective validation of ELF test in comparison with Fibroscan and FibroTest to predict liver fibrosis in Asian subjects with chronic hepatitis B. |
| Q47165308 | Proteome-based identification of apolipoprotein A-IV as an early diagnostic biomarker in liver fibrosis |
| Q26782440 | Quantification of liver fibrosis in chronic hepatitis B virus infection. |
| Q35679627 | Quantification of liver fibrosis via second harmonic imaging of the Glisson's capsule from liver surface |
| Q52692830 | Quantitative Elastography Methods in Liver Disease: Current Evidence and Future Directions |
| Q35818743 | Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: Results from the hepatitis C antiviral long-term treatment against cirrhosis trial |
| Q41047662 | Recommendations for the management of hepatitis C virus infection among people who inject drugs |
| Q42280296 | Recommendations for the management of hepatitis C virus infection among people who inject drugs. |
| Q84710800 | Reduction of liver stiffness by antiviral therapy in chronic hepatitis B |
| Q39560512 | Reproducibility of liver stiffness measurements in hepatitis C virus (HCV)-infected patients in Egypt. |
| Q43104809 | Reversal of liver fibrosis |
| Q38074087 | Role of liver biopsy in the era of direct-acting antivirals. |
| Q51848337 | SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. |
| Q42735003 | Serologic markers of hepatic fibrosis. |
| Q51278552 | Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C. |
| Q41707920 | Serum hyaluronic acid in chronic viral hepatitis B and C: a biomarker for assessing liver fibrosis in chronic hemodialysis patients. |
| Q27022470 | Shear wave elastography for evaluation of liver fibrosis |
| Q50109194 | Shear wave liver elastography. |
| Q36643026 | Systematic review of the diagnostic performance of serum markers of liver fibrosis in alcoholic liver disease |
| Q30383680 | T2 relaxation time is related to liver fibrosis severity. |
| Q42758500 | The Diagnostic Value of Ultrasound Elastography in Patients with Hepatitis B Virus Infection: A Prospective Study |
| Q64066713 | The Effect of Splenectomy on the Reversal of Cirrhosis: a Prospective Study |
| Q104748009 | The Within-Individual Reproducibility of the Disease Severity Index from the HepQuant SHUNT® Test of Liver Function and Physiology |
| Q35194722 | The effectiveness of noninvasive biomarkers to predict hepatitis B-related significant fibrosis and cirrhosis: a systematic review and meta-analysis of diagnostic test accuracy |
| Q30458426 | The efficacy of aspartate aminotransferase-to-platelet ratio index for assessing hepatic fibrosis in childhood nonalcoholic steatohepatitis for medical practice |
| Q38117079 | The efficiency of acoustic radiation force impulse imaging for the staging of liver fibrosis: a meta-analysis |
| Q37682493 | Tools for the diagnosis of hepatitis C virus infection and hepatic fibrosis staging. |
| Q28084154 | Transient Elastography and Controlled Attenuation Parameter for Diagnosing Liver Fibrosis and Steatosis in Ontario: An Economic Analysis |
| Q26776180 | Transient Elastography for Assessment of Liver Fibrosis and Steatosis: An Evidence-Based Analysis |
| Q91789114 | Transient Elastography in the Evaluation of Cystic Fibrosis-Associated Liver Disease: Systematic Review and Meta-analysis |
| Q45358861 | Transient elastography and simple blood markers in the diagnosis of esophageal varices for compensated patients with hepatitis B virus‐related cirrhosis |
| Q34417027 | Transient elastography for the noninvasive assessment of liver fibrosis: a multicentre Canadian study |
| Q38135774 | Treatment decisions and contemporary versus pending treatments for hepatitis C. |
| Q38102394 | Ultrasound elastography in liver |
| Q33684186 | Urinary procollagen III aminoterminal propeptide (PIIINP): a fibrotest for the nephrologist. |
| Q87620928 | Usefulness of transient elastography by FibroScan for the evaluation of liver fibrosis |
| Q84385952 | Utility of liver function tests including aminotransferase-to-platelet ratio index in monitoring liver dysfunction in short-gut infants of varying ages and intestinal lengths |
| Q35030432 | Variations in DEPDC5 gene and its association with chronic hepatitis C virus infection in Saudi Arabia |
| Q41392739 | WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 3: liver |
| Q58622697 | Évaluation non-invasive de la fibrose hépatique au cours de l’hépatite C |
Search more.